Enterprise Europe Network

Polish biotech spin-off company producing innovative bone substitution biomaterial is looking for distributors

Country of origin:
External Id: 
Last update
Expiration date


Partner keyword: 
Biochemistry / Biophysics
Other manufacturing (not elsewhere classified)
Research and experimental development on biotechnology


Spin-off company based in the eastern part of Poland offers innovative, implantable biomaterial for effective treatment of bone defects. The product (the so-called "artificial bone") is dedicated for traumatic surgery, orthopaedics, craniofacial and veterinary surgery. The main advantages for users are surgical handiness, high specific surface area and high ability to absorb. The company is looking for distributors.



The spin-off company emerged from the fusion of scientists (inventors and patent authors) and private capital is located in the eastern part of Poland. The company's product is innovative implantable biomaterial allowing for effective treatment of bone defects. The product is designed particularly to fill the defects resulting from traffic accidents, located in long bones and craniofacial bones, and defects after the removal of bone tumours and post-infective cysts. The company's product is dedicated for trauma surgery, orthopaedics, craniofacial surgery and veterinary surgery and can also potentially be used in treatment of bone defects resulting from osteoporotic bone tissue fractures. This material can be used in dental surgery. Besides, the biomaterial can also be used as a bioactive filling of titanium and polyester scaffolds used in implant surgery.
In order to expand into new markets, the company is willing to coopearte with foreign partners under distribution agreement.

Advantages & innovations

Cooperation plus value: 
The main individual features of company's product are as follows: Surgical handiness, which allows to adjust it during surgery to the shape of individual bone defects by cutting or bending. In a dry state, material can be milled which enables the personalization of the composite implant. High specific surface area (due to the high microporosity of granules), high ionic reactivity (adsorption of calcium and phosphate ions from surroundings liquid which allows to increase the rate of mineralization. Application of carbohydrate polymer to produce the material composite minimizes the risk of viruses and prions contamination. Curdlan undegoes gelling, forming the structure of irreversible, collagen-like triple helix – the conformation which is neutral for macrophages and does not evoke the appearance of local inflammation. The product has exhibit high soaking capacity and can be easily stored and transported.

Stage of development

Cooperation stage dev stage: 
Already on the market

Partner sought

Cooperation area: 
The partner's role as a distributor should be responsibility for sale and distribution of the biomaterial to the hospitals, private clinics. An advantage would be if the partner has contacts with the hospitals.

Type and size

Cooperation task: 
SME 11-50,SME <10,SME 51-250


Dissemination sector group : 
Dissemination preferred : 
Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, Luxembourg, Moldova, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom